177: Impact of elexacaftor/tezacaftor/ivacaftor therapy use on pulmonary exacerbation rates during the COVID-19 pandemic
Keyword(s):
2017 ◽
Vol 13
(4)
◽
pp. 307-313
◽
2016 ◽
Vol 15
(6)
◽
pp. 783-790
◽